Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.55 |
| ▸ | CLK1 | P49759 | 3/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | TRIM33 | Q9UPN9 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209308 | 0.90 | FYN (0.55) | FYNCLK1DYRK1ACA1CA2 | |
| SCHEMBL3491072 | 0.88 | ALDH1A1 (0.60) | FYNCLK1DYRK1ACA1CA2 | |
| SCHEMBL25148814 | 0.87 | CHEK1 (0.46) | FYNRIPK2ATMKDM4ENPC1 | |
| SCHEMBL25149584 | 0.84 | MKNK1 (0.44) | FYNCLK1DYRK1ATRIM33RIPK2 | |
| SCHEMBL3850100 | 0.83 | PIK3CA (0.53) | FYNRIPK2ATMKDM4E | |
| SCHEMBL25149690 | 0.81 | FYN (0.49) | FYNTRIM33RIPK2TRIM24ATM | |
| SCHEMBL18609148 | 0.80 | PIK3CA (0.58) | FYNCLK1ATM | |
| SCHEMBL15298893 | 0.80 | MKNK1 (0.50) | FYNCLK1RIPK2FLT3ATM | |
| SCHEMBL30399843 | 0.79 | MKNK1 (0.45) | FYNTRIM33RIPK2TRIM24ATM | |
| SCHEMBL3854288 | 0.79 | PIK3CA (0.65) | FYNCLK1DYRK1ATRIM33RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | FYN 920/4885CLK1 2065/4885DYRK1A 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.